The involvement of IL1B may also be interesting from a therapeutic point of view, as anti-IL1B agents were shown to significantly decrease the risk of a new cardiovascular event in myocardial infarction patients in a large RCT (CANTOS study; Ridker et al., 2011). Here, IL1B is linked to myocardial infarction.